
Retatrutide Just Hit Bariatric-Surgery Numbers in Phase 3. The FDA Says Wait Until 2027.
Lilly's TRIUMPH-1 just posted 28.3% average body weight loss at 80 weeks. That's bariatric surgery territory, from a single weekly injection. The NDA filing is Q4 2026. FDA approval is 2027 at the earliest. Here's what the data says, what it means for tirzepatide users, and the access conversation nobody wants to have.




















